Trending

#Syndax

Latest posts tagged with #Syndax on Bluesky

Latest Top
Trending

Posts tagged #Syndax

Wooden blocks spelling “AML” with a stethoscope beside them, representing Syndax Pharmaceuticals’ focus on Acute Myeloid Leukemia treatment.

Wooden blocks spelling “AML” with a stethoscope beside them, representing Syndax Pharmaceuticals’ focus on Acute Myeloid Leukemia treatment.

#SNDX presented new data at #EHA2025 showing nearly half of patients with tough-to-treat mNPM1 AML responded to Revuforj. Median survival for responders hit 23.3 months. FDA decision expected later this year.
#Syndax
prismmarketview.com/syndax-share...

0 0 0 0
Preview
FDA Approves Niktimvo: A Game-Changer for Chronic GVHD Patients Niktimvo's FDA approval marks a major advance in chronic GVHD treatment, targeting inflammation and fibrosis with proven efficacy across various patient groups.

FDA Approves Niktimvo: A Game-Changer for Chronic GVHD Patients #United_States #Wilmington #Niktimvo #Syndax #Incyte

0 0 0 0
Preview
Syndax Pharmaceuticals to Showcase Innovations at J.P. Morgan Healthcare Conference Syndax Pharmaceuticals will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, showcasing its innovative cancer therapies and company achievements.

Syndax Pharmaceuticals to Showcase Innovations at J.P. Morgan Healthcare Conference #United_States #Revuforj #Niktimvo #Syndax #Waltham,_Massachusetts

0 0 0 0
Preview
Syndax Showcases Promising Revuforj® Data for Acute Leukemia at ASH Annual Meeting Syndax Pharmaceuticals revealed significant data on Revuforj® (revumenib) for treating acute leukemias at the 66th ASH Annual Meeting, demonstrating high efficacy and tolerability in patients.

Syndax Showcases Promising Revuforj® Data for Acute Leukemia at ASH Annual Meeting #United_States #San_Diego #Revuforj #Syndax #acute_leukemia

0 0 0 0